These PD-1-targeted agents have found expansive application in the therapeutic landscape of SCLC, with pembrolizumab demonstrating noteworthy antitumor efficacy, particularly in patients harboring pretreated, PD-L1 expressing SCLC. The gene discussed is CD274; the disease is small cell lung carcinoma.